The benefits of combined therapy include lowering serum glucose and body weight, and comfortable accessibility.[15,16] However, it is unclear whether T2D patients who have previously received premixed insulin therapy and poor blood sugar control can increase the compliance of injection therapy due to the enhanced control of blood sugar and body weight through the combined injection of GLP-1-RA and basal insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.